121 related articles for article (PubMed ID: 34128222)
21. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.
Dey AK; Joshi AA; Chaturvedi A; Lerman JB; Aberra TM; Rodante JA; Teague HL; Harrington CL; Rivers JP; Chung JH; Kabbany MT; Natarajan B; Silverman JI; Ng Q; Sanda GE; Sorokin AV; Baumer Y; Gerson E; Prussick RB; Ehrlich A; Green LJ; Lockshin BN; Ahlman MA; Playford MP; Gelfand JM; Mehta NN
JAMA Cardiol; 2017 Sep; 2(9):1013-1018. PubMed ID: 28564678
[TBL] [Abstract][Full Text] [Related]
22. Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene.
Kearney N; Kirby B
Am J Clin Dermatol; 2022 Nov; 23(6):881-890. PubMed ID: 35997945
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
24. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
25. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J; Roosenboom B; van de Kerkhof PC; van den Reek JM; Otero ME; Atalay S; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Bijen M; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
27. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.
Naldi L; Addis A; Chimenti S; Giannetti A; Picardo M; Tomino C; Maccarone M; Chatenoud L; Bertuccio P; Caggese E; Cuscito R
Dermatology; 2008; 217(4):365-73. PubMed ID: 18810241
[TBL] [Abstract][Full Text] [Related]
28. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
[TBL] [Abstract][Full Text] [Related]
29. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment.
Karpińska-Mirecka A; Bartosińska J; Krasowska D
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948777
[TBL] [Abstract][Full Text] [Related]
32. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988
[TBL] [Abstract][Full Text] [Related]
33. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
34. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
35. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France.
Maza A; Richard MA; Aubin F; Ortonne JP; Prey S; Bachelez H; Beylot-Barry M; Bulai-Livideanu C; Lahfa M; Nougué J; Mengual X; Le Moigne M; Lauwers-Cances V; Paul C
Br J Dermatol; 2012 Sep; 167(3):643-8. PubMed ID: 22512545
[TBL] [Abstract][Full Text] [Related]
36. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
37. Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Rissler M; Gathmann S; Sieder C; Baeumer D; Orsenigo R
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2548-2556. PubMed ID: 32239541
[TBL] [Abstract][Full Text] [Related]
38. Alcohol misuse and outpatient follow-up after hospital discharge: a retrospective cohort study.
Borg B; Douglas IS; Hull M; Keniston A; Moss M; Clark BJ
Addict Sci Clin Pract; 2018 Dec; 13(1):24. PubMed ID: 30514357
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
40. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain.
Fernández-Torres RM; Pita-Fernández S; Fonseca E
Int J Dermatol; 2014 Nov; 53(11):e507-11. PubMed ID: 25266080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
